Evaluation of Interferon-Gamma Responses to HCMV Infection in HIV Positive Individuals
Information source: The Alfred
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infection; CMV Disease
Phase: N/A
Status: Recruiting
Sponsored by: The Alfred Official(s) and/or principal investigator(s):
Sharon Lewin, Professor, Principal Investigator, Affiliation: The Alfred
Overall contact:
Sharon Lewin, Professor, Phone: 0061 3 9276 3009, Email: Sharon.Lewin@alfred.org.au
Summary
The study is designed to evaluate interferon responses to CMV in HIV positive individuals
and a component will look at interferon responses to CMV in HIV positive individuals over
time after commencement of antiretroviral therapy. We will also look at the correlation
between CD4 T cell numbers and HLA type with the interferon response.
Clinical Details
Official title: Evaluation of Interferon-Gamma Responses to HCMV Infection in HIV Positive Individuals
Study design: Cohort, Prospective
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HIV positive with history of documented HCV infection
- > 18 years old
- HIV positive
- Antiretroviral, starting on therapy (cross sectional study)
- > 18 years old (longitudinal study)
Locations and Contacts
Sharon Lewin, Professor, Phone: 0061 3 9276 3009, Email: Sharon.Lewin@alfred.org.au
Alfred Hospital, Melbourne, Victoria 3004, Australia; Recruiting
Sharon Lewin, Professor, Phone: 0061 3 9276 3009, Email: Sharon.Lewin@alfred.org.au
Additional Information
Starting date: December 2004
Last updated: May 16, 2008
|
